Olawale Osuntokun
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Schizophrenia research and treatment, Dermatology and Skin Diseases, Bipolar Disorder and Treatment, Asthma and respiratory diseases
Most-Cited Works
- → Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis(2016)822 cited
- → Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials(2015)818 cited
- → A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia(2011)255 cited
- → A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder(2007)227 cited
- → Therapeutic Options for Treatment-Resistant Depression(2010)205 cited
- → Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)(2016)190 cited
- → Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis(2018)118 cited
- → Olanzapine plus carbamazepinev.carbamazepine alone in treating manic episodes(2008)76 cited
- → A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia(2009)66 cited
- → An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression(2009)65 cited